Skip to Main Content

Robyn Karnauskas’s biotech blue skies have turned dark and stormy.

During the biotech boom-boom years, Citi’s large-cap biotech analyst earned a reputation for being eternally sunny. To Karnauskas, every drug was a blockbuster. Buy ratings were bountiful. Price targets moved in only one direction: up.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.